180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Update

180 Life Sciences Corp. (NASDAQ:ATNF) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 126,900 shares, a decrease of 21.1% from the December 31st total of 160,800 shares. Based on an average daily volume of 2,280,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 7.6% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 180 Life Sciences in a report on Saturday, January 18th.

180 Life Sciences Price Performance

Shares of ATNF traded down $0.04 on Friday, hitting $1.40. 77,876 shares of the stock traded hands, compared to its average volume of 250,080. 180 Life Sciences has a one year low of $1.16 and a one year high of $17.75. The business has a 50 day simple moving average of $1.89 and a 200 day simple moving average of $2.20.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.